{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2"},{"groupId":"OG001","value":"91.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"Subjects achieving graft durability were defined as meeting the following 2 criteria:\n\n* Platelet count ≥50 × 10\\^9/L without transfusion for at least 2 weeks.\n* Hemoglobin level ≥10 g/dL with no erythropoietin support or transfusions for at least 1 month.\n\nThis analysis was performed in part 2 of the study only.","groups":[{"description":"Part 2: randomized, double-blinded, placebo-controlled period. G-CSF given one time daily s.c. for 5-8 days (Day 1 up to 8) at doses of approximately 10 µg/kg/day but not more than 15 µg/kg/day. BL-8040 1.25 mg/kg s.c. on Day 4 (and Day 6, if needed).\n\nFirst apheresis on Day 5 with up to 3 additional procedures possible until Day 8, as needed.","id":"OG000","title":"BL-8040 + G-CSF Part 2"},{"description":"Part 2: randomized, double-blinded, placebo-controlled period. G-CSF given one time daily s.c. for 5-8 days (Day 1 up to 8) at doses of approximately 10 µg/kg/day but not more than 15 µg/kg/day. Placebo s.c. on Day 4 (and Day 6, if needed).\n\nFirst apheresis on Day 5 with up to 3 additional procedures possible until Day 8, as needed.","id":"OG001","title":"Placebo + G-CSF Part 2"}],"paramType":"NUMBER","populationDescription":"Post Transplantation analysis set (all randomized subjects treated, with at least 1 apheresis session, and who underwent transplantation).\n\nGraft durability was not assessed during Part 1 of the study.","reportingStatus":"POSTED","timeFrame":"Day 100 Post-Transplantation (± 7 days)","title":"Subjects With Graft Durability at 100 Days Post Transplant/ Early Termination","type":"SECONDARY","unitOfMeasure":"Percentage of responders"}